Evidence map›Paper›PMID 30143535›Full record

ArticleThe Journal of biological chemistry2018

Membrane cholesterol as regulator of human rhomboid protease RHBDL4.

Sandra Paschkowsky, Sherilyn Junelle Recinto, Jason C Young, Ana-Nicoleta Bondar, Lisa Marie Munter

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Sandra PaschkowskyFrom the Department of Pharmacology and Therapeutics and Cell Information Systems Group and.
Sherilyn Junelle RecintoFrom the Department of Pharmacology and Therapeutics and Cell Information Systems Group and.
Jason C YoungDepartment of Biochemistry and Groupe de Recherche Axé sur la Structure des Protéines, McGill University, Montreal, Quebec H3G 0B1, Canada and.
Ana-Nicoleta Bondarthe Department of Physics, Theoretical Molecular Biophysics, Freie Universität Berlin, Arnimallee 14, Berlin 14195, Germany.
Lisa Marie MunterFrom the Department of Pharmacology and Therapeutics and Cell Information Systems Group and lisa.munter@mcgill.ca.
McGill University · CAFreie Universität Berlin · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the last decade, intramembrane proteases have gained increasing attention because of their many links to various diseases. Nevertheless, our understanding as to how they function or how they are regulated is still limited, especially when it comes to human homologues. In this regard, here we sought to unravel mechanisms of regulation of the protease rhomboid-like protein-4 (RHBDL4), one of five active human serine intramembrane proteases. In view of our recent finding that human RHBDL4 efficiently cleaves the amyloid precursor protein (APP), a key protein in the pathology of Alzheimer's disease, we used established reagents to modulate the cellular cholesterol content and analyzed the effects of this modulation on RHBDL4-mediated processing of endogenous APP. We discovered that lowering membrane cholesterol levels increased the levels of RHBDL4-specific endogenous APP fragments, whereas high cholesterol levels had the opposite effect. Direct binding of cholesterol to APP did not mediate these modulating effects of cholesterol. Instead, using homology modeling, we identified two potential cholesterol-binding motifs in the transmembrane helices 3 and 6 of RHBDL4. Substitution of the essential tyrosine residues of the potential cholesterol-binding motifs to alanine increased the levels of endogenous APP C-terminal fragments, reflecting enhanced RHBDL4 activity. In summary, we provide evidence that the activity of RHBDL4 is regulated by cholesterol likely through a direct binding of cholesterol to the enzyme.

Indexed as

Amino Acid SequenceAmyloid beta-Protein PrecursorAnticholesteremic AgentsBinding SitesCell MembraneCholesterolGene Expression RegulationHEK293 CellsHumansLipoproteins, LDLMembrane ProteinsMetalloproteasesMitochondrial ProteinsModels, MolecularProprotein ConvertasesProtein BindingAmyloid beta-Protein PrecursorAnticholesteremic AgentsAPP protein, humanCholesterolLipoproteins, LDLmembrane-bound transcription factor peptidase, site 1Membrane ProteinsMetalloproteasesMitochondrial ProteinsPARL protein, humanProprotein ConvertasesRHBDL3 protein, humanSerine EndopeptidasesSimvastatinSterol Regulatory Element Binding ProteinsAlzheimer's diseaseamyloid precursor protein (APP)cholesterolcholesterol-binding proteincholesterol pulldowncholesterol recognition amino acid consensus sequence (CRAC)intramembrane proteolysislarge APP C-terminal fragmentslow-density lipoprotein (LDL)neurodegenerationrhomboid protease

Identifiers

PMID30143535
PMCPMC6177575
OpenAlexW2889543660

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.